Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products.
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... As part of an ongoing ... in its network and logistics capabilities to meet ... the complex requirements of the industry. , The ... logistics and transportation, and includes opening new QuickSTAT ... will be an emphasis on Customer Service capabilities, ...
(Date:11/15/2014)... 14, 2014 The "Operating Room ... Performance), by Application (Perioperative, Preoperative, operating room Scheduling), ... On-Premise) - Global Forecast to 2019.” defines and ... analysis and forecast of value by product, such ... with this, the value and volumes of operating ...
(Date:11/15/2014)... November 14, 2014 ... the addition of the  "Protein Characterization and ... Application, & by End Users - Global ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The global protein ... $1,569.00 million in 2014, and is expected ...
(Date:11/12/2014)... , Nov. 12, 2014  ReachBio Research Labs (a ... WA ) announced today that it has signed ... Japan ), giving Funakoshi non-exclusive distribution rights to ... science research market within Japan . ... specialized contract research services to Japanese drug development companies. ...
Breaking Biology Technology:QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 2Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 3Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 2Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 3
... Amgen Foundation,s ... Million Applications for 2009 Amgen Scholars ... 10 Each year, hundreds of,students from across the ... renowned faculty members at the country,s leading,universities. Now, the ...
... /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology ... products primarily in China,today announced that it has ... (SFDA) for approval of NuLeusin for the treatment ... NuLeusin is expected to,be the only treatment of ...
... design provides more options for treating patients with ... Boston Scientific,Corporation (NYSE: BSX ) today announced ... and Drug Administration to market its Apex(TM) PTCA(1),Dilatation ... catheter developed specifically to address physicians, needs in,treating ...
Cached Biology Technology:Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe 2Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe 3Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 2FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 3FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 4
(Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
(Date:11/4/2014)... CORAL GABLES, Fla. (November 4, 2014) — Think about ... and ask: How do neighboring cells know that they ... cell and how do these tissues find the correct ... (UM) are answering these crucial questions. , In a ... tissues use to communicate with their surrounding neighbors, at ...
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... scientists who first created "mighty mice" have developed, with ... agent that's more effective at increasing muscle mass in ... now in clinical trials. , The new agent is ... muscle-limiting protein myostatin. In mice, just two weekly injections ...
... Howard Hughes Medical Institute (HHMI) researchers have deciphered a key ... in the spinal cord connect to specific target muscles in ... may help guide progress in restoring motor neuron function in ... disease. The studies suggest that the code -- which involves ...
... today presented preliminary safety and efficacy data for E7389 ... the San Antonio Breast Cancer Symposium. E7389 is ... a natural product shown in preclinical studies to have ... Halichondrin B was originally isolated from a type of ...
Cached Biology News:Mouse study: New muscle-building agent beats all previous ones 2Scientists crack code for motor neuron wiring 2Scientists crack code for motor neuron wiring 3Scientists crack code for motor neuron wiring 4Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer 2
Immunogen: Synthetic peptide: R(89) L A F T V D D N P T K P T T R Q R Y(107) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... The OneSTrEP Protein Interaction Kit ... single step method to isolate intact ... require tedious optimization or multiple purification ... the highly selective StrepTactin Superflow Column ...
... from different Cynomolgus monkey normal tissues ... available upon request. Customers can ... whole set, and pay 70% of ... Dr. P Set products are for ...
Biology Products: